title: Stage-dependent alterations of progenitor cell proliferation and neurogenesis in an animal model of Wernicke-Korsakoff syndrome.
abstract: Alcohol-induced Wernicke-Korsakoff syndrome (WKS) culminates in bilateral diencephalic lesion and severe amnesia. Using the pyrithiamine-induced thiamine deficiency (PTD) animal paradigm of WKS, our laboratory has demonstrated hippocampal dysfunction in the absence of gross anatomical pathology. Extensive literature has revealed reduced hippocampal neurogenesis following a neuropathological insult, which might contribute to hippocampus-based learning and memory impairments. Thus, the current investigation was conducted to determine whether PTD treatment altered hippocampal neurogenesis in a stage-dependent fashion. Male Sprague-Dawley rats were assigned to one of 4 stages of thiamine deficiency based on behavioral symptoms: pre-symptomatic stage, ataxic stage, early post-opisthotonus stage, or the late post-opisthotonus stage. The S-phase mitotic marker 5'-bromo-2'-deoxyuridine (BrdU) was administered at the conclusion of each stage following thiamine restoration and subjects were perfused 24 hours or 28 days after BrdU to assess cellular proliferation or neurogenesis and survival, respectively. Dorsal hippocampal sections were immunostained for BrdU (proliferating cell marker), NeuN (neurons), GFAP (astrocytes), Iba-1 (microglia), and O4 (oligodendrocytes). The PTD treatment increased progenitor cell proliferation and survival during the early post-opisthotonus stage. However, levels of neurogenesis were reduced during this stage as well as the late post-opisthotonus stage where there was also an increase in astrocytogenesis. The diminished numbers of newly generated neurons (BrdU/NeuN co-localization) was paralleled by increased BrdU cells that did not co-localize with any of the phenotypic markers during these later stages. These data demonstrate that long-term alterations in neurogenesis and gliogenesis might contribute to the observed hippocampal dysfunction in the PTD model and human WKS.
authors: Department of Psychology, Behavioral Neuroscience, State University of New York at Binghamton, Vestal, NY 13902, USA. rvetren1@binghamton.edu
authors: Ryan P
authors: RP
authors: Vetreno
authors: Anna
authors: A
authors: Klintsova
authors: Lisa M
authors: LM
authors: Savage
mesh_terms: D000818:Animals; D001835:Body Weight / Q000502:physiology; D001973:Bromodeoxyuridine / Q000378:metabolism; D002452:Cell Count / Q000379:methods; D049109:Cell Proliferation; D002552:Cerebral Ventricles / Q000473:pathology*; D004195:Disease Models, Animal; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D020915:Korsakoff Syndrome / Q000473:pathology*; D008297:Male; D018613:Microscopy, Confocal; D055495:Neurogenesis / Q000502:physiology*; D010751:Phosphopyruvate Hydratase / Q000378:metabolism; D011745:Pyrithiamine / Q000009:adverse effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D013234:Stem Cells / Q000502:physiology*; D013832:Thiamine Deficiency / Q000139:chemically induced / Q000473:pathology
chemical_list: D005904:Glial Fibrillary Acidic Protein; D011745:Pyrithiamine; D010751:Phosphopyruvate Hydratase; D001973:Bromodeoxyuridine